Cephalon/Chiron Myotrophin
Executive Summary
FDA cancellation of the April 9 Peripheral and Central Nervous System Drugs Advisory Committee meeting will "allow the agency to continue its review" of the mecasermin NDA, Cephalon said. FDA said that "further analyses of the data by the agency and sponsor were not complete and ready for discussion." The agency has not indicated if the meeting will be rescheduled. The meeting would have been the committee's third to discuss Myotrophin for amyotrophic lateral sclerosis. The user fee goal date for Myotrophin is May 11...